A 28-year-old woman presents to the emergency department with fever (38.5°C), severe oral pain, and difficulty swallowing for 3 days. She reports a maculopapular rash that started on her face and trunk 2 days ago and has now spread to involve her palms and soles. On examination, she has extensive oral ulceration, conjunctival injection, and target lesions with central blistering on her extremities. Her lips show hemorrhagic crusting. She had taken trimethoprim-sulfamethoxazole for a urinary tract infection 10 days ago. Skin biopsy shows full-thickness epidermal necrosis with minimal dermal inflammation. What is the most appropriate immediate management?

Explanation

## Clinical Diagnosis: Stevens-Johnson Syndrome (SJS) **Key Point:** This patient meets diagnostic criteria for SJS based on: - Prodromal fever and systemic symptoms - Characteristic target lesions with central blistering - Mucosal involvement (oral ulceration, conjunctival injection, lip crusting) - Temporal relationship to trimethoprim-sulfamethoxazole (TMP-SMX is a classic culprit) - Skin biopsy showing full-thickness epidermal necrosis ## Management Algorithm ```mermaid flowchart TD A[SJS/TEN Diagnosis Confirmed]:::outcome --> B[Immediate Actions]:::action B --> B1[Stop offending drug immediately] B --> B2[Transfer to ICU/Burn unit] B --> B3[Fluid & electrolyte resuscitation] B1 --> C{Extent of Involvement?}:::decision C -->|< 10% BSA| D[Supportive care + monitoring]:::action C -->|10-30% BSA| E[Consider IVIG or Cyclosporine]:::action C -->|> 30% BSA| F[IVIG 2g/kg or Cyclosporine]:::action D --> G[Avoid systemic corticosteroids]:::urgent E --> G F --> G ``` **High-Yield:** The cornerstone of SJS/TEN management is **immediate discontinuation of the offending drug**. Unlike many dermatologic emergencies, systemic corticosteroids are NOT first-line and may increase infection risk and mortality in severe cases [cite:Harrison 21e Ch 56]. **Clinical Pearl:** The patient's skin biopsy showing full-thickness epidermal necrosis with minimal dermal inflammation is pathognomonic for SJS/TEN and distinguishes it from other severe drug reactions (e.g., DRESS, which shows prominent dermal inflammation). **Warning:** Do NOT delay drug withdrawal while awaiting further investigations. Every hour counts in preventing disease progression. ## Supportive Care Essentials | Intervention | Rationale | |---|---| | IV fluid resuscitation (Parkland formula) | Prevent hypovolemic shock; estimate 1–1.5 L/% BSA affected | | Electrolyte monitoring & correction | Massive fluid loss mimics burn injury | | Nutritional support (NG feeding) | Oral ulceration prevents oral intake | | Ophthalmology consultation | Prevent corneal scarring and blindness | | Avoid NSAIDs, antibiotics (except proven safe) | Risk of triggering or worsening reaction | **Mnemonic:** **STOP SJS** = **S**top drug, **T**ransfer to ICU, **O**phthalmic care, **P**erfusion support, **S**upportive measures, **J**oin multidisciplinary team, **S**econd opinion on corticosteroids. ## Role of Immunosuppression - **Systemic corticosteroids:** Controversial; meta-analyses show no mortality benefit and possible increased infection risk. Avoid unless severe mucosal involvement threatens airway. - **IVIG:** May be considered in severe cases (>30% BSA) or rapidly progressive disease, but evidence is mixed. - **Cyclosporine:** Emerging evidence suggests benefit in severe TEN; not standard in SJS. **Key Point:** The absence of systemic corticosteroids in the immediate management is the critical differentiator in this question.